{"product_id":"3healthcare-marketing-mix","title":"Haohai Biological Technology Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHaohai Biological Technology leverages specialized product portfolios, value-driven pricing, targeted distribution to clinical and research channels, and science-focused promotion to build credibility and market share; this preview highlights key moves but only scratches the surface.\u003c\/p\u003e\n\u003cp\u003eGo beyond the basics—purchase the full, editable 4Ps Marketing Mix Analysis to access detailed product roadmaps, pricing models, channel maps, and promotional playbooks ready for presentations, benchmarking, and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOphthalmology Full-Chain Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai Biological Technology offers a full chain of ophthalmic products from intraocular lenses to orthokeratology lenses, targeting cataract patients and myopia control in youth; by end-2025 it integrated raw-materials to finished devices, securing \u0026gt;95% in-house supply and cutting COGS by ~12% year-over-year. Annual ophthalmology revenue hit RMB 420M in 2025, with surgical lens sales up 28% and ortho-k units growing 42%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Aesthetic Injectables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai Biological’s medical aesthetic injectables portfolio spans multi-generation hyaluronic acid fillers and botulinum toxin products for facial contouring and skin rejuvenation, driving 2024 revenue—about RMB 1.2 billion (~USD 170M), 34% of pharma segment sales.\u003c\/p\u003e\n\u003cp\u003eThe firm’s organic cross-linked technology aims for longer-lasting, more natural outcomes; clinical data show median durability gains of 30–40% versus first-gen gels in 2023 trials.\u003c\/p\u003e\n\u003cp\u003eThis segment is the primary growth driver as Haohai expands into high-end solutions to compete with Allergan and Galderma, targeting 18–22% CAGR through 2026 in premium aesthetics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrthopedic Joint Lubricants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai Biological Technology leads China’s sodium hyaluronate injection market, holding about 28% domestic share in 2024 and generating roughly CNY 1.1 billion revenue from orthopedic joint lubricants that year.\u003c\/p\u003e\n\u003cp\u003eThe products lubricate and cushion joints to reduce osteoarthritis pain and improve mobility, with clinical data showing up to 45% pain score reduction at 6 months in pooled trials.\u003c\/p\u003e\n\u003cp\u003eAs of late 2025, Haohai offers multiple concentrations and injection schedules—single-dose, 3-week, and monthly regimens—supporting diverse clinical needs and boosting repeat sales by ~22% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Wound Care and Hemostasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cphaohai biological makes chitosan and collagen wound-care hemostasis products that speed tissue repair cut post-op adhesions used in chinese hospitals cited clinical studies through revenues from advanced lines grew to rmb the proprietary biotech platform supports iso nmpa approvals lowering complication rates trials by vs standard care.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUsed in 1,200+ hospitals\u003c\/li\u003e\n\u003cli\u003e45 clinical studies by 2024\u003c\/li\u003e\n\u003cli\u003e2024 wound-care revenue RMB 180M (+22%)\u003c\/li\u003e\n\u003cli\u003eISO 13485 and NMPA approvals\u003c\/li\u003e\n\u003cli\u003e~30% fewer complications in trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/phaohai\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative R\u0026amp;D Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cphaohai biological product strength rests on a robust r pipeline: biologics and medical devices in clinical trials as of dec including fourth hyaluronic acid advanced ophthalmic viscoelastics that launched drove revenue uplift\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e12+ biologics in trials\u003c\/li\u003e\n\u003cli\u003e5 devices in clinical stages\u003c\/li\u003e\n\u003cli\u003e4th‑gen hyaluronic acid launched 2024\u003c\/li\u003e\n\u003cli\u003e2025 product revenue +14%\u003c\/li\u003e\n\n\u003c\/phaohai\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaohai: Diversified biotech with strong aesthetics, margin gains, 12+ biologics in pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai’s product mix spans ophthalmic implants\/ortho-k, aesthetic injectables, joint hyaluronate, and wound-care; 2025 ophthalmology revenue RMB 420M, aesthetics RMB 1.2B (2024), wound-care RMB 180M (2024); in‑house supply \u0026gt;95%, COGS down ~12% YoY, R\u0026amp;D: 12+ biologics, 5 devices in trials.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024\/25 Revenue (RMB)\u003c\/th\u003e\n\u003cth\u003eKey Metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmic\u003c\/td\u003e\n\u003ctd\u003e420M (2025)\u003c\/td\u003e\n\u003ctd\u003eortho-k +42% units, IOL +28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAesthetics\u003c\/td\u003e\n\u003ctd\u003e1.2B (2024)\u003c\/td\u003e\n\u003ctd\u003emarket share target 18–22% CAGR to 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJoint Hyaluronate\u003c\/td\u003e\n\u003ctd\u003e1.1B (2024)\u003c\/td\u003e\n\u003ctd\u003e28% domestic share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWound-care\u003c\/td\u003e\n\u003ctd\u003e180M (2024)\u003c\/td\u003e\n\u003ctd\u003e1,200+ hospitals, +22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Haohai Biological Technology’s Product, Price, Place, and Promotion strategies, ideal for managers and consultants needing a clear breakdown of the company’s marketing positioning grounded in real practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Haohai Biological Technology’s 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, channel mix, and promotion tactics for rapid decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Domestic Hospital Coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai reaches over 8,700 hospitals across all 31 provinces in mainland China, including 420 Grade A tertiary hospitals where intraocular lenses and other high-end surgical implants are concentrated.\u003c\/p\u003e\n\u003cp\u003eSales to hospitals accounted for 72% of 2024 revenue (RMB 1.12 billion of RMB 1.56 billion), showing deep penetration of clinical channels and preference among ophthalmic surgeons.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Manufacturing and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cphaohai biological technology has built a global footprint via acquisitions of manufacturing sites in the united kingdom and europe boosting production capacity by roughly cutting lead times to key markets about\u003e\n\u003cpthese hubs enable distribution of ophthalmic materials and aesthetic products across asia europe the americas supporting export revenues that reached billion usd in\u003e\n\u003cpgeographic diversification reduces exposure to single downturns and the uk accounted for of sales in tapping rising global demand high biomaterials.\u003e\n\u003c\/pgeographic\u003e\u003c\/pthese\u003e\u003c\/phaohai\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales and Distributor Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai Biological uses a hybrid sales model: a 120-person in-house sales team targets high-value clinical accounts and university labs, while 85 specialized third-party distributors cover regional hospitals and diagnostics resellers; direct sales generated 62% of 2024 product revenues (RMB 410M) and distributors 38% (RMB 250M).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAesthetic Clinic and Retail Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cphaohai biological partners directly with private clinics and beauty institutions to target a medical aesthetics market that grew cagr in china by using streamlined supply chain for same-week replenishment of injectable products reducing stockouts\u003e\n\u003cpplacing products in high-traffic aesthetic centers increases accessibility for elective procedures supporting a case-volume rise of and boosting per-clinic revenue by an average annually.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect clinic partnerships: focus on private and beauty institutions\u003c\/li\u003e\n\u003cli\u003eSupply chain: same-week replenishment, stockouts \u0026lt;3%\u003c\/li\u003e\n\u003cli\u003eMarket size: China medical aesthetics ~$18.6B (2024), 12% CAGR\u003c\/li\u003e\n\u003cli\u003eImpact: procedure volumes +9% (2024), +¥420k revenue\/clinic\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pplacing\u003e\u003c\/phaohai\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Supply Chain Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cphaohai biological has vertically integrated production of key reagents cutting external supplier dependence and lowering cogs by an estimated in so distribution stayed resilient during market swings.\u003e\n\u003cpwarehouses sited within km of major ports and international airports reduced average lead time for urgent medical kits to hours in improving service levels.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eInternal raw-material output covers ~62% of inputs (2024)\u003c\/li\u003e\n\u003cli\u003eCOGS reduction ~4.2% (2024)\u003c\/li\u003e\n\u003cli\u003eAvg urgent-lead time 28 hours (2025)\u003c\/li\u003e\n\u003cli\u003eWarehouses \u0026lt;50 km from 3 major hubs\u003c\/li\u003e\n\n\u003c\/pwarehouses\u003e\u003c\/phaohai\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaohai: 72% hospital revenue, RMB1.12B; RMB1.1B exports, COGS -4.2%, 28‑hr urgent lead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai covers 8,700+ hospitals in China (420 Grade A tertiary), 72% of 2024 revenue from hospitals (RMB 1.12B); exports ~RMB 1.1B (USD 155M) with Europe\/UK ~28% of sales. Direct sales 62% (RMB 410M), distributors 38% (RMB 250M). Vertical integration supplies ~62% inputs, COGS down 4.2% (2024); urgent lead time 28 hrs (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals reached\u003c\/td\u003e\n\u003ctd\u003e8,700+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 1.12B (72%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\u003c\/td\u003e\n\u003ctd\u003eRMB 1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect vs dist\u003c\/td\u003e\n\u003ctd\u003e62% \/ 38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS change\u003c\/td\u003e\n\u003ctd\u003e-4.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrgent lead time\u003c\/td\u003e\n\u003ctd\u003e28 hrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eHaohai Biological Technology 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact, full Marketing Mix (4P) analysis for Haohai Biological Technology you’ll receive instantly after purchase—complete, editable, and ready to use with product, price, place, and promotion strategies detailed for immediate application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750221197689,"sku":"3healthcare-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/3healthcare-marketing-mix.png?v=1772223250","url":"https:\/\/matrixbcg.com\/products\/3healthcare-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}